Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has granted fast track designation for Achillion Pharmaceuticals' ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C (HCV).
Subscribe to our email newsletter
ACH-3102 is a pan-genotypic second-generation NS5A inhibitor against HCV that is currently being evaluated in a Phase I trial.
Achillion president and chief executive officer Michael Kishbauch said fast track designation highlights ACH-3102’s attributes that include pan-genotypic coverage of HCV and potential for maintained activity against NS5A mutant strains of HCV.
"We are excited to leverage the superior profile of ACH-3102 in combination with our Phase 2 protease inhibitor, ACH-1625, as we seek to create an optimized, potentially best-in-class potent, well-tolerated, once-daily regimen to treat HCV, which will enter combination studies during the third quarter of this year," Kishbauch added.
Fast Track designation was requested for ACH-3102 for its potential to provide improved safety, potent antiviral activity in vitro against HCV genotypes 1 through 6 and low potential for drug-drug interactions.